Kyverna's Miv-cel Shows Positive Results In Phase 2 KYSA-8 Trial For Stiff Person Syndrome- Update

Kyverna Therapeutics reported positive Phase 2 KYSA-8 data for mivocabtagene (miv-cel), an autologous CD19 CAR-T for stiff person syndrome, showing a median 46% improvement in timed 25-foot walk at Week 16 with 81% of patients achieving >20% improvement and broad benefits on disability, stiffness and ambulation (two‑thirds of previously aided walkers no longer required assistance); all patients remained off immunotherapies, none required rescue therapy, and no high‑grade CRS or ICANS were reported. The company plans to file a BLA in H1 2026 and is advancing a broader autoimmune CAR‑T franchise (registrational KYSA‑6 in generalized myasthenia gravis, early‑stage MS and RA programs, and next‑gen KYV‑102 with rapid whole‑blood manufacturing) intended to expand access and lower COGS. Kyverna ended Sept. 30, 2025 with $171.1M in cash plus $25M drawn on a $150M facility (runway into 2027), and the stock jumped ~39.5% premarket to $12.25, a 52‑week high.

Analysis

Kyverna Therapeutics reported positive registrational Phase 2 KYSA-8 results for mivocabtagene (miv-cel) in stiff person syndrome, enrolling 26 adults; at Week 16 the median timed 25-foot walk improved 46% and 81% of patients achieved >20% improvement, with broad secondary gains in disability, stiffness and ambulation. Of 12 patients who required walking aids pre-treatment, two-thirds no longer needed assistance by Week 16, all patients remained off immunotherapies and none required rescue therapy, and no high-grade CRS or ICANS were observed, supporting a favorable acute safety profile. These outcomes form the basis for a planned BLA submission in H1 2026 and represent a potential first-in-class readthrough for autoimmune CAR T therapy where no FDA-approved options exist.

Kyverna is progressing a suite of autoimmune programs: KYSA-6 (registrational Phase 2/3 in generalized myasthenia gravis with Phase-3 enrolment planned), Phase 1 activity in MS and RA showing CNS penetration and antibody reductions, and KYV-102 (IND expected Q4 2025) tied to a whole-blood rapid manufacturing approach to reduce COGS. The company reported $171.1M cash as of Sept 30, 2025 plus an initial $25M draw on a $150M facility, giving management-forecast runway into 2027, and the stock jumped pre-market to $12.25 (up 39.52%) to a new 52-week high after trading between $1.78 and $9.75 over the past year.

While Week 16 efficacy and tolerability materially de-risk the program, risks remain from the small single-arm sample (N=26), limited durability data, potential regulatory scrutiny at BLA review, manufacturing scale-up and reimbursement uncertainties, and likely future dilution given cash runway constraints. Investors should weigh the meaningful clinical signal against execution and financing risks ahead of confirmatory data and regulatory decisions.

Key Decisions for Investors

• Consider a measured buy or add on strength to gain exposure to a high-upside, first-in-class autoimmune CAR-T story while limiting position size due to small N and short follow-up
• Monitor near-term catalysts closely: BLA timing in H1 2026, Phase-3 enrolment updates for KYSA-6, IND timing for KYV-102 in Q4 2025, and any regulatory feedback
• Prioritize safety and durability readouts and manufacturing scale-up evidence before increasing exposure, and be prepared for dilution given runway into 2027
• Use protective sizing or hedges to limit downside from regulatory setbacks or financing-driven dilution